相关临床试验
1
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
已完成
1
100.0%
暂无批准数据
- Adial Pharmaceuticals announced the publication of an international PCT patent application for AD04, its lead genetically targeted serotonin-3 receptor antagonist for treating Alcohol Use Disorder in heavy drinking patients. - The patent, filed in July 2024 and expected to be granted, will protect Adial's core assets through at least 2045, significantly extending the company's intellectual property exclusivity. - AD04 targets heavy drinking patients defined as consuming fewer than 10 drinks per drinking day and is being developed for a new Phase 3 clinical trial program using the company's proprietary diagnostic genetic test. - The therapy showed promising results in the ONWARD study, demonstrating reduced drinking in heavy drinking patients with no overt safety or tolerability concerns.
- Adial Pharmaceuticals successfully validated a cheek swab genetic test with Genomind to identify patients suitable for AD04 therapy in upcoming Phase 3 trials. - The test identifies specific genetic variants in the serotonergic system, with the AG+ biomarker present in approximately 14% of the general population. - FDA confirmed the genetic test poses Non-Significant Risk for Phase 3 studies, eliminating the need for an Investigational Device Exemption application. - The validated assay demonstrated 100% concordance across all single nucleotide polymorphism testing and can be easily administered in physician offices or at home.
- The U.S. Senate Appropriations Committee passed bipartisan legislation encouraging the FDA to develop alternative clinical trial endpoints for Alcohol Use Disorder beyond abstinence, including reduced cravings and decreased disorder severity. - Adial Pharmaceuticals' AD04, a serotonin-3 receptor antagonist currently in Phase 3 development, is positioned to benefit from these new patient-focused regulatory pathways for AUD treatment. - The legislative support validates Adial's therapeutic approach of reducing alcohol consumption and cravings rather than enforcing complete abstinence, addressing significant unmet medical needs in addiction treatment.
- Adial Pharmaceuticals has received a six-figure milestone payment from Adovate following the initiation of a Phase 1 clinical trial for ADO-5030, a novel adenosine receptor antagonist targeting asthma. - The Single Ascending Dose study will evaluate safety, tolerability, and pharmacokinetics of ADO-5030 in healthy volunteers, with the compound positioned as a potential first-line therapy for the underserved global asthma market. - Under the agreement terms, Adial is eligible to receive up to $83 million in milestone payments for the first three compounds alone, plus royalties and retains over 10% equity stake in Adovate.
- Adial Pharmaceuticals' AD04 demonstrated predictable bioavailability and dose proportionality in a recent pharmacokinetics study, AD04-103. - The study confirmed that AD04, a selective 5-HT3 antagonist, can be taken with or without food, simplifying administration for patients. - These results support Adial's plans to seek FDA approval for AD04 under the 505(b)(2) pathway, with an End-of-Phase 2 meeting targeted for the first half of the year. - AD04 is being developed for AUD patients with a specific 5-HT3 genomic biomarker, potentially enhancing drug binding and efficacy.
